Literature DB >> 2404527

Intravenous immunoglobulin for secondary immunodeficiency.

P L Yap1.   

Abstract

Viral and bacterial infections are a serious cause of morbidity and mortality in patients immunocompromised as a result of malignancy, burns, trauma, viral infections or chemotherapy. The development of safe and effective antibody preparations suitable for intravenous use have transformed the lives of patients suffering from forms of primary immunodeficiency characterised by antibody deficiency. However, the role of intravenous immunoglobulin (IV IgG) preparations in the treatment of secondary immunodeficiencies is less clear and although many anecdotal reports exist for the use of IV IgG in various secondary immunodeficiencies (Table 1), there have been few controlled trials of a sufficient size that have demonstrated clear-cut efficacy in many of the suggested new indications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2404527     DOI: 10.1007/bf01720196

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  38 in total

Review 1.  Immunoglobulin therapy in bone marrow transplantation.

Authors:  K M Sullivan
Journal:  Am J Med       Date:  1987-10-23       Impact factor: 4.965

2.  Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial.

Authors:  Robert Peter Gale; Helen M Chapel; Christopher Bunch; Kanti R Rai; Kenneth Foon; Suzanne G Courter; Dierdre Tait
Journal:  N Engl J Med       Date:  1988-10-06       Impact factor: 91.245

3.  Intravenous immune globulin: a cautionary note.

Authors:  A S Cross; B M Alving; J C Sadoff; P Baldwin; H Terebelo; D Tang
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

4.  Intravenous immunoglobulin for prophylaxis of neonatal sepsis in premature infants.

Authors:  A Stabile; S Miceli Sopo; V Romanelli; M Pastore; M A Pesaresi
Journal:  Arch Dis Child       Date:  1988-04       Impact factor: 3.791

5.  Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens.

Authors:  G R Siber; P H Schur; A C Aisenberg; S A Weitzman; G Schiffman
Journal:  N Engl J Med       Date:  1980-07-24       Impact factor: 91.245

Review 6.  Immunosuppression and infection in multiple myeloma.

Authors:  D R Jacobson; S Zolla-Pazner
Journal:  Semin Oncol       Date:  1986-09       Impact factor: 4.929

7.  Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial.

Authors:  T Calandra; M P Glauser; J Schellekens; J Verhoef
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

8.  [Efficacy of intravenous gammaglobulin in bacterial infections in Surgical Patients. Results of a controlled, randomized clinical study (author's transl)].

Authors:  K H Duswald; K Müller; J Seifert; J Ring
Journal:  MMW Munch Med Wochenschr       Date:  1980-05-30

9.  Pneumococcal infections after human bone-marrow transplantation.

Authors:  D J Winston; G Schiffman; D C Wang; S A Feig; C H Lin; E L Marso; W G Ho; L S Young; R P Gale
Journal:  Ann Intern Med       Date:  1979-12       Impact factor: 25.391

10.  Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.

Authors:  R J Jones; E A Roe; J L Gupta
Journal:  Lancet       Date:  1980-12-13       Impact factor: 79.321

View more
  2 in total

Review 1.  The immunologic response to thermal injury.

Authors:  M Heideman; A Bengtsson
Journal:  World J Surg       Date:  1992 Jan-Feb       Impact factor: 3.352

2.  High-dose IgG for neutropenic patients with acquired immunodeficiency syndrome (AIDS).

Authors:  A Salama; J Lohmeyer; W Seeger; C Mueller-Eckhardt
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.